|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
03320 CHINARES PHARMA
Nominal 
5.370 -0.050 (-0.923%) Ranking Overview
Ranking based on 6 research report(s)
Average Ranking 2.00
|
Strong Buy (1)
0
|
Buy (2)
6
|
Hold (3)
0
|
Sell (4)
0
|
Strong Sell (5)
0
|
Previous Financial Performance
| Financial Year | 12/2023 | EPS | 61.00 RMB (cts) | |
| Net Profit | 3,854.25 RMB (MIL) | DPS | 15.40 RMB (cts) |
Consolidation Estimation
| Financial Year | Profit / (Loss) (RMB (MIL)) |
EPS/ ((LPS)(RMB (cts)) |
DPS (RMB (cts)) |
Net Asset Value per Share (RMB) |
Highest (RMB (MIL)) |
Lowest (RMB (MIL)) |
| 2024 | 4,351.50 | 69.40 | 16.00 | -- | 5,158.00 | 4,062.00 |
| 2025 | 4,760.00 | 75.50 | 17.41 | -- | 5,746.00 | 4,397.00 |
| 2026 | 5,151.00 | 82.00 | 18.00 | -- | 6,098.00 | 4,773.00 |
Profit Estimation
| Profit Estimation | Profit / (Loss) (RMB (MIL)) |
EPS*/ (LPS) (RMB (cts)) |
DPS * (RMB (cts)) |
Broker | Ranking | Target Price* (HKD) |
Update Date | |
| 2024 | 4,232.00 | 67.00 | 15.00 | UBS | Buy | 9.90 | 18/10/2024 | |
| 2024 | 5,158.00 | 82.00 | 14.84 | MORGAN STANLEY | Overweight | 8.00 | 03/09/2024 | |
| 2024 | 4,315.00 | 69.00 | 17.00 | CICC | OutPerform | 7.30 | 31/08/2024 | |
| 2024 | 4,388.00 | 69.80 | 17.50 | CLSA | OutPerform | 6.80 | 30/08/2024 | |
| 2024 | 4,399.00 | 70.00 | 18.00 | CCBI | OutPerform | 6.40 | 29/08/2024 | |
| 2024 | 4,062.00 | 64.60 | 14.80 | BANK OF AMERICA | Buy | 5.90 | 19/09/2024 | |
| 2025 | 4,680.00 | 74.00 | 16.00 | UBS | -- | -- | 18/10/2024 | |
| 2025 | 5,746.00 | 91.00 | 16.82 | MORGAN STANLEY | -- | -- | 03/09/2024 | |
| 2025 | 4,840.00 | 77.00 | 19.00 | CICC | -- | -- | 31/08/2024 | |
| 2025 | 5,097.00 | 81.10 | 20.30 | CLSA | -- | -- | 30/08/2024 | |
| 2025 | 4,573.00 | 73.00 | 18.00 | CCBI | -- | -- | 29/08/2024 | |
| 2025 | 4,397.00 | 70.00 | 16.00 | BANK OF AMERICA | -- | -- | 19/09/2024 | |
| 2026 | 5,098.00 | 81.00 | 18.00 | UBS | -- | -- | 18/10/2024 | |
| 2026 | 6,098.00 | 97.00 | 17.81 | MORGAN STANLEY | -- | -- | 03/09/2024 | |
| 2026 | 5,843.00 | 93.00 | 23.30 | CLSA | -- | -- | 30/08/2024 | |
| 2026 | 5,151.00 | 82.00 | 20.00 | CCBI | -- | -- | 29/08/2024 | |
| 2026 | 4,773.00 | 76.00 | 17.30 | BANK OF AMERICA | -- | -- | 19/09/2024 | |
| Remarks: | Average rating ranges from 1 to 5. The lower the figure, the higher the rating and the vice versa. |
| *EPS, DPS and Estimated Price would be adjusted upon Consolidation, Split and Bonus Issue | |
| Real time quote last updated: 15/11/2024 17:59 | |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 2,604,806 |
| %Change | -2.866% |
| EPS / (LPS) | RMB 0.410 |
| NBV Per Share (¥) | RMB 7.699 |